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Abstract
Human herpesviruses (HHVs) have a particularly high prevalence in certain high‐risk
populations and cause increased morbidity and mortality in patients with acquired
immunodeficiency syndrome (AIDS). Screening and treating subclinical HHV
infections reduce human immunodeficiency virus (HIV) infection incidence, disease
progression, and transmission. However, there are few studies on HHVs, HIV
coinfection rates, and their related risk factors. We aimed to clarify the prevalence of
all eight HHVs in peripheral blood samples collected from HIV‐positive patients, and
explore the association of HHV infection in HIV‐positive patients in an HIV‐
seropositive population in Yunnan. We recruited 121 HIV‐positive patients with
highly active antiretroviral therapy (HAART) and 45 healthy individuals. All the eight
HHVs were detected using polymerase chain reaction and their epidemiological
information and clinical data were collected and statistically analyzed. A high
prevalence of HHVs (89.3%) was observed in individuals with HIV infections and with
herpes simplex virus (HSV)‐2 (65.3%), and HSV‐1 (59.5%) being the most common.
Coinfection with more than two different HHVs was more common in patients with
HIV infections receiving HAART (72.7%) than in healthy controls. Older age, being
married, higher HIV‐1 plasma viral loads, and use of antiviral protease inhibitors were
independently correlated with an increased frequency of HHVs, but we found no
association with CD4 count, WHO HIV clinical stage, and HIV infection duration. Our
findings are of great significance for the prevention of HHV opportunistic infection in
patients with AIDS and their clinical treatment.
K E YWORD S
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1 | INTRODUCTION
Human immunodeficiency virus (HIV) mainly infects helper T cells
of the immune system and eventually leads to acquired
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immunodeficiency syndrome (AIDS).1 HIV infection is becoming a
global health issue due to high morbidity and mortality, and
comparatively the situation may be worse in Yunnan. By the end of
2016, approximately 93 437 people were estimated to be living with
HIV in Yunnan. This province has been considered the epicenter of
HIV‐1 in China, and was the first to conduct highly active
antiretroviral therapy (HARRT) in China.2 The course of infection
of HIV‐1 is characterized by a long interval between initial infection
and the onset of serious symptoms as T cell numbers are gradually
reduced. HIV infection is associated with an increased risk for human
herpesviruses (HHVs) and related diseases, such as AIDS‐associated
oral lymphoma and oral hairy leukoplakia.3
HHVs belong to the Herpesviridae family and are widely
distributed viruses that cause benign and malignant disease in
animals and humans. They are ubiquitous and have a particularly
high prevalence in certain high‐risk populations, causing increased
morbidity and mortality in patients with AIDS.4 There are eight
known herpes family viruses associated with human infection:
herpes simplex virus (HSV) types 1 and 2, varicella‐zoster virus
(VZV), Epstein‐Barr virus (EBV), cytomegalovirus (CMV), human
herpesvirus 6 (HHV‐6), human herpesvirus 7 (HHV‐7), and human
herpesvirus 8 (HHV‐8). These viruses have both epidemiologic
and clinical interactions with HIV‐1, which are associated with
serious opportunistic infections and their reactivation predicts
poor outcome.5,6
Normal host immune response may control and limit HHV
replication, but reactivation of latent infection can result in severe
opportunistic infections with high morbidity and mortality in
immunocompromised subjects.7,8 Furthermore, some HHVs might
interact with HIV‐1 or have a role as a cofactor for HIV‐1
progression, accelerating the replication of HIV‐1.9 At the same
time, HIV‐1 can facilitate acquisition and reactivation of HHVs as
HIV‐1 and HHVs are involved in a vicious cycle.10 Prevalence rates
and viral loads are influenced by the biological properties of the virus,
method of detection, frequency of sampling, whether symptomatic or
not, social behaviors, and immunological status of the patient.11
Detection using polymerase chain reaction (PCR) assay shows that
the frequencies of these viruses are wide‐ranging across a variety of
clinical samples12-14 and are influenced by the degree of immuno-
depression,15,16 geography, and behavioral risk factors.17-19 Suppres-
sion of HHV recurrence by cotherapy had a clinically significant
effect on prolonged survival in some cohorts of HIV‐infected
patients.20
Zhaotong is located on a drug transmission route far from the
border between China and other Southeast Asian countries. It may
be the smallest affected area of the Yunnan Province to have an
external strain HIV‐1 that is indigenous. The seroprevalence rates
and predictive factors of HHV in the setting of HIV‐1 infections in
Zhaotong have not been explored. In this study, we aimed to identify
the prevalence of all eight HHVs in peripheral blood samples
collected from HIV‐positive patients and explore the association of
HHV infection in HIV‐positive patients while adjusting for potential
confounding factors.
2 | METHODS
2.1 | Study participants
A total of 121 HIV‐positive patients were randomly selected from 2517
cases of HIV infection that were treated in The First People’s Hospital of
Zhaotong City from May 2015 to February 2016. At the same time, we
recruited a control group of 45 healthy, HIV‐negative subjects, matched
for age at the time of examination. The inclusion criterion for both
groups was that they be without symptoms of acute illness (fever,
headache, sore throat, body aches, and diarrhea) and malignancy at the
time of enrollment. The exclusion criterion included pregnancy, use of
immunosuppressant medications, and administration of antiherpetic
therapy within 1 week before the date of study enrollment. Plasma
samples from all subjects were stored at −80°C until DNA was
extracted. The study was approved by the Ethics Committee of The First
Affiliated Hospital of Kunming Medical University. Verbal consent was
obtained from all the participants before enrollment in the study.
2.2 | HHV infection detection
Viral DNA was extracted from 200 μL of plasma using the TIANamp
Genomic DNA kit (TIANGEN, Beijing, China) according to the
manufacturer’s instructions. The DNA was subjected to nested PCR
to amplify the fragments of HSV‐1, HSV‐2, VZV, EBV, HCMV, HHV‐6,
HHV‐7, and HHV‐8 with the outer and inner oligonucleotide primers
designed for this study. Each sample was tested in duplicate and scored
as positive or negative in case of concordant results. When results
were discordant, two new aliquots were examined, and the sample was
regarded as positive if at least two of four examinations were positive.
PCR products were run on 2% agarose gel stained with ethidium
bromide and visualized under a UV light transilluminator and sent to a
commercial sequencing location (Invitrogen, Beijing, China).
2.3 | Epidemiological information and clinical data
Data on the social‐demographic characteristics of these participants
as well as the informed consent to participate in this study were
obtained from the enrolled participants during the face‐to‐face
interview by the outpatient doctor. Clinical data were also collected
from the hospital laboratory information system, including a blood
biochemical analytical index and CD4 lymphocyte count.
2.4 | Statistical analysis
Statistical analyses were conducted using the SPSS software (IBM SPSS
Statistics for Windows, Version 19.0; IBM Corp, Armonk, NY). The χ2
and Fisher’s exact tests were applied to compare the demographic
characteristics distribution and seroprevalence rates between the two
groups. Logistic regression was used to calculate adjusted odds ratios
and 95% confidence intervals on the association of the eight HHVs and
multiple HHV infections with socio‐demographic and biological risk
factors. The results were considered statistically significant if P < .05.
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3 | RESULTS
3.1 | Demographic characteristics of study
participants
The 166 participants were from 11 different areas of the Zhaotong
prefecture. Among the HIV‐positive and healthy HIV‐negative
groups, the ratio of male to female participants was 77:44 in the
HIV‐positive group and 20:25 in the control group. The mean age
of the participants was 42 ± 14.0 years in the HIV group and
40 ± 12.2 years in the control group. The majority of the subjects
were in the age range 31 to 40 with some over 41 years of age,
with a distribution of 38% and 46.3% in the HIV group, and 37.8%
and 26.7% in the control group. The majority of the subjects were
married, accounting for 73.6% in the HIV group and 66.7% in the
control group, followed by unmarried (12.4% vs 28.9%), divorced
(7.4% vs 2.2%), widowed (5.8% vs 2.2%), and other/unknown (0.8%
vs 0.0%). No significant differences among demographic charac-
teristics were observed between either groups. Sexual transmis-
sion was the main HIV infection route and several were infected by
sharing drug needles.
3.2 | HHVs infection status
In total, among 108 HIV‐positive individuals were positive for
HHV with at least one HHV infection. The prevalence of HHV was
higher (89.3%) in peripheral blood of HIV‐positive group than the
control group (62.2%). The most prevalent viruses in the HIV
group were HSV‐2 (65.3%) and HSV‐1 (59.5%), followed by HHV‐8
(42.2%), HHV‐6 (32.2%), EBV (16.5%), HHV‐7 (15.6%), HCMV
(5.0%), and VZV (1.7%). In contrast, HHV‐8 (28.9%) and HHV‐6
(20.0%) were the most prevalent viruses in the control group,
followed by HSV‐1 (17.8%), HSV‐2 (11.1%), HHV‐7 (6.7%), and
VZV (2.2%), but EBV and HCMV were not detected in this group
(Figure 1A). There was not enough data on the seroprevalence of
CMV and HCMV for accurate statistical analysis. Statistical
analysis indicated that there were significant differences in the
presence of HSV‐1 (P < .001), HSV‐2 (P < .001), and EBV (P < .01)
between the two groups.
The number of double and triple HHV infections were 33 and 30
in HIV‐positive group, respectively, higher than a single infection.
Three cases were found to have six HHV infections (one was negative
for VZV and EBV and two showed failure to detect VZV and HCMV).
Coinfection with multiple HHVs was more likely to occur in the HIV
group than in the control group, especially coinfection with more
than two different HHVs (P < .001), and this difference was found to
be statistically significant. However, the control group was more
likely to be coinfected with only one HHV (P < .01) (Figure 1B).
3.3 | Related predictive factors in HIV group
Statistical analysis of demographic and clinical information was
performed to further uncover the relationship between different
predictive factors and eight HHV infections in HIV‐1‐positive
patients.
Age was the most relevant factor for single HHV infections in the
HIV group and significant differences were observed for the risk of
infection by HHV‐1 (P < .001), HSV‐2 (P = .049), HHV‐6 (P < .01), and
HHV‐8 (P = .001) at different age stages (Table 1). The infection rates
among those older than 31 years were especially higher than among
others. Marital status was another leading risk for HHV; infections
(HSV‐2, HHV‐6, and HHV‐8) were much higher among married
patients. Infections by EBV and HHV‐7 were also associated with
different immune statuses. Low CD4 counts were correlated with
infection by EBV (P = .010) and HHV‐7 (P = .044). A noteworthy
observation is that HIV viral load only influenced EBV infection, and
EBV infection decreased with the increase of HIV viral load (P = .013).
Current HAART regimens using double nucleoside reverse‐tran-
scriptase inhibitors (NRTIs) and single nonnucleoside reverse‐
transcriptase inhibitors (NNRTIs) therapy can slightly increase the
risk for infection by HSV‐1 (P = .049) and HHV‐8 (P = .044).
Furthermore, for infection by HSV‐1, males were more at risk than
females (P = .029), and for infection by EBV, people with HIV‐1
transmitted by intravenous drug use and sexual activity were more
F IGURE 1 Seroprevalence rates of (A) single or (B) multiple HHV infection in peripheral blood as determined by nested PCR. χ2 and Fisher’s
exact tests were used to test the differences between the HIV group and the control; the significant differences are indicated with asterisks.
HHV, human herpesviruse; HIV, human immunodeficiency virus; PCR, polymerase chain reaction
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likely to be infected (P < .001). Surprisingly, there were no significant
differences in the seroprevalence of the eight HHVs with different
WHO stages and durations of HIV infection, which were thought to
be related to organism immunization.
The results of HHV detection showed that patients with HIV
were more likely to have greater than 2 HHV infections with
different viruses. Multiple HHV infections were found to be
significantly associated with age, marital status, CD4 cell counts,
and current HAART regimen in HIV‐positive patients, but not related
to HIV viral load and WHO stage (Table 2). The proportion of
coinfection with multiple viruses was higher in married and older
adults (above 41 years old), indicating that they were at a greater risk
of having multiple infections. Similarly, different medication regimens
of HARRT were also shown to influence multiple HHV infections
(P = .011). The patients simultaneously using NRTIs with NNRTIs
were more likely to have multiple infections. Multiple HHV
TABLE 1 Single HHVs infection and related predictive factors in HIV group
Characteristics
Seroprevalence rate
HSV‐1 HSV‐2 VZV EBV HCMV HHV‐6 HHV‐7 HHV‐8
Total, no. (%) 72 (59.5) 79 (65.3) 2 (1.7) 20 (16.5) 6 (5) 39 (32.2) 19 (15.7) 51 (42.1)
Sex, no. (%) P = .029 P = .377 P = .533 P > .999 P = .085 P > .999 P = .409 P = .986
Male 52 (43) 53 (43.8) 2 (1.7) 13 (10.7) 6 (5.0) 25 (20.7) 10 (8.3) 33 (27.3)
Female 20 (16.5) 26 (21.5) 0 (0.0) 7 (5.8) 0 (0.0) 14 (11.6) 9 (7.4) 18 (14.9)
Age, no. (%), y P < .001 P = .049 P = .645 P = .275 P > .999 P < .01 P = .600 P = .001
≤20 0 (0.0) 1 (0.8) 0 (0.0) 2 (1.7) 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0)
21‐30 4 (3.3) 8 (6.6) 0 (0.0) 2 (1.7) 0 (0.0) 2 (1.7) 1 (0.8) 1 (0.8)
31‐40 26 (21.5) 28 (23.1) 0 (0.0) 5 (4.1) 3 (2.5) 10 (8.3) 6 (5.0) 18 (14.9)
≥41 42 (34.7) 42 (34.7) 2 (1.7) 11 (9.1) 3 (2.5) 27 (22.3) 11 (9.1) 32 (26.4)
Marital status, no. (%)a P = .279 P = .016 P > .999 P = .199 P > .999 P = .032 P = .655 P = .026
Unmarried 6 (5.0) 5 (4.1) 0 (0.0) 5 (4.1) 0(0.0) 1 (0.8) 1 (0.8) 4 (3.3)
Married 56 (46.3) 61 (50.4) 2 (1.7) 13 (10.7) 5(4.1) 30 (24.8) 16 (13.2) 35 (28.9)
Others/unknown 10 (8.3) 13 (10.7) 0 (0.0) 2 (1.7) 1(0.8) 8 (6.6) 2 (1.7) 12 (9.9)
CD4 (cells/µL), no. (%) P = .089 P = .660 P > .999 P = .010 P = .576 P = .275 P = .044 P = .273
≤200 26 (21.5) 25 (20.7) 1 (0.8) 6 (5.0) 2 (1.7) 9 (7.4) 11 (9.1) 14 (11.6)
201‐399 28 (23.1) 31 (25.6) 1 (0.8) 7 (5.8) 4 (3.3) 17 (14.0) 5 (4.1) 26 (21.5)
≥400 16 (13.2) 19 (15.7) 0 (0.0) 2 (1.7) 0 (0.0) 12 (9.9) 3 (2.5) 8 (6.6)
Others/unknown 2 (1.7) 4 (3.3) 0 (0.0) 5 (4.1) 0 (0.0) 1 (0.8) 0 (0.0) 3 (2.5)
WHO stage, no. (%) P = .499 P = .226 P > .999 P = .581 P = .663 P = .201 P = .739 P = .981
Stage I/II 51 (42.1) 57 (47.1) 2(1.7) 12 (9.9) 5 (4.1) 30 (24.8) 14 (11.6) 34 (28.1)
Stage III/IV 21 (17.4) 22 (18.2) 0(0.0) 8 (6.6) 1 (0.8) 9 (7.4) 5 (4.1) 17 (14.0)
HIV viral load (copies/mL), no. (%) P = .072 P = .051 P = .521 P = .013 P = .340 P = .154 P = .747 P = .914
Undetectable 19 (15.7) 20 (16.5) 0 (0.0) 5 (4.1) 1 (0.8) 14 (11.6) 7 (5.8) 18 (14.9)
<1000 13 (10.7) 13 (10.7) 0 (0.0) 4 (3.3) 0 (0.0) 4 (3.3) 3 (2.5) 8 (6.6)
1000‐9999 19 (15.7) 22 (18.2) 1 (0.8) 3 (2.5) 2 (1.7) 7 (5.8) 5 (4.1) 12 (9.9)
≥10 000 18 (14.9) 19 (15.7) 1 (0.8) 2 (1.7) 3 (2.5) 12 (9.9) 4 (3.3) 9 (7.4)
Others/unknown 3 (2.5) 5 (4.1) 0 (0.0) 6 (5.0) 0 (0.0) 2 (1.7) 0 (0.0) 4(3.3)
Transmission category, no. (%) P = .256 P = .863 P = .461 P < .001 P = .816 P = .068 P = .387 P = .912
IDU 8 (6.6) 10 (8.3) 1 (0.8) 8 (6.6) 0 (0.0) 2 (1.7) 4 (3.3) 8 (6.6)
Sexual 57 (47.1) 59 (48.8) 1 (0.8) 8 (6.6) 5 (4.1) 34 (28.1) 12 (9.9) 37 (30.6)
MCT/others/unknown 7 (5.8) 10 (8.3) 0 (0.0) 4 (3.3) 1 (0.8) 3 (2.5) 3 (2.5) 6 (5.0)
HIV infection duration, no. (%), y P = .276 P = .342 P = .305 P = .152 P > .999 P = .264 P = .991 P = .226
1 7 (5.8) 8 (6.6) 1 (0.8) 4 (3.3) 1 (0.8) 5 (4.1) 3 (2.5) 6 (5.0)
2 31 (25.6) 31 (25.6) 0 (0.0) 3 (2.5) 2 (1.7) 19 (15.7) 7 (5.8) 24 (19.8)
3 16 (13.2) 18 (14.9) 0 (0.0) 6 (5.0) 1 (0.8) 9 (7.4) 5 (4.1) 12 (9.9)
≥4 17 (14.0) 21 (17.4) 1 (0.8) 6 (5.0) 2 (1.7) 6 (5.0) 4 (3.3) 8 (6.6)
Others/unknown 1 (0.8) 1 (0.8) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
Current HAART regimen P = .049 P = .256 P > .999 P = .431 P = .628 P = .148 P > .999 P = .044
Double‐NRTIs + NNRTIs 64 (52.9) 68 (56.2) 2 (1.7) 18 (14.9) 5 (4.1) 32 (26.4) 17 (14.0) 48 (39.7)
Double‐NRTIs + PIs 8 (6.6) 10 (8.3) 0 (0.0) 1 (0.8) 1 (0.8) 7 (5.8) 2 (1.7) 3 (2.5)
Others/unknown 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Note: The statistically significant are presented with italic bold.
Abbreviations: HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IDU, intravenous drug use; MCT, mother‐to‐child
transmission; NRTIs, nucleoside reverse‐transcriptase inhibitors; NNRTIs, nonnucleoside reverse‐transcriptase inhibitors; PIs, protease inhibitors.
aOthers/unknown include divorced, widowed, and others/unknown.
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infections were much higher in patients with lower CD4 cell counts
(<400 cells/μL), and especially in subjects with CD4 cell counts of
201 to 399 cells/μL.
4 | DISCUSSION
Yunnan has been the hardest hit region by HIV in China with more
than 90 000 patients with AIDS by 2016, and the first place to
introduce HAART in China. Although HARRT has a beneficial
treatment effect, opportunistic infections by other viruses, and
bacteria present significant difficulties. HHVs have been infecting
humans for hundreds of millions of years and can significantly affect
morbidity and mortality rates when coinfected with HIV. Screening
and treating subclinical HHV infections may offer a slowing of HIV
infection, disease progression, and its transmission. This study was
initiated to evaluate the seroprevalence rates and correlates of
peripheral blood among eight HHVs as well as multiple HHVs in
asymptomatic, HIV‐seropositive persons treated with HAART.
TABLE 2 Multiple HHVs infection and related predictive factors in HIV group
Characteristics Subjects 0 1 ≥2 χ2 P
Total, no. (%) 121 (100.0) 13 (10.7) 20 (16.5) 88 (72.7)
Sex, no. (%) 3.210 .187
Male 77 (63.6) 6 (5.0) 11 (9.1) 69 (49.6)
Female 44 (36.4) 7 (5.8) 9 (7.4) 28 (23.1)
Age, no. (%), y 28.960 <.001
≤20 5 (4.1) 2 (1.7) 2 (1.7) 1 (0.8)
21‐30 14 (11.6) 4 (3.3) 4 (3.3) 6 (5.0)
31‐40 46 (38.0) 7 (5.8) 9 (7.4) 30 (24.8)
≥41 56 (46.3) 0 (0.0) 5 (4.1) 51 (42.1)
Marital status, no. (%)a 10.333 .020
Unmarried 15 (12.4) 4 (3.3) 5 (4.1) 6 (5.0)
Married 89 (73.6) 9 (7.4) 13 (10.7) 67 (55.4)
Others/unknown 17 (14.0) 0 (0.0) 2 (1.7) 15 (12.4)
CD4 (cells/µL), no. (%) 14.154 .017
≤200 36 (29.8) 0 (0.0) 9 (7.4) 27 (22.3)
201‐399 50 (41.3) 9 (7.4) 4 (3.3) 37 (30.6)
≥400 27 (22.3) 4 (3.3) 4 (3.3) 19 (15.7)
Others/unknown 8 (6.6) 0 (0.0) 3 (2.5) 5 (4.1)
WHO stage, no. (%) 1.368 .536
Stage I/II 82 (67.8) 7 (5.8) 14 (11.6) 61 (50.4)
Stage III/IV 39 (32.2) 6 (5.0) 6 (5.0) 27 (22.3)
HIV viral load (copies/mL), no. (%) 13.068 .077
Undetectable 38 (31.4) 6 (5.0) 7 (5.8) 25 (20.7)
＜1000 22 (18.2) 5 (4.1) 2 (1.7) 15 (12.4)
1000‐9999 27 (22.3) 0 (0.0) 5 (4.1) 22 (18.2)
≥10 000 24 (19.8) 2 (1.7) 2 (1.7) 20 (16.5)
Others/unknown 10 (8.3) 0 (0.0) 4 (3.3) 6 (5.0)
Transmission category, no. (%) 2.289 .704
IDU 17 (14.0) 1 (0.8) 3 (2.5) 13 (10.7)
Sexual 89 (73.6) 10 (8.3) 13 (10.7) 66 (54.5)
MCT/others/unknown 15 (12.4) 2 (1.7) 4 (3.3) 9 (7.4)
HIV infection duration, no. (%), y 9.487 .251
1 16 (13.2) 1 (0.8) 4 (3.3) 11 (9.1)
2 44 (36.4) 3 (2.5) 5 (4.1) 36 (29.8)
3 29 (24.0) 6 (5.0) 4 (3.3) 19 (15.7)
≥4 29 (24.0) 3 (2.5) 5 (4.1) 21 (17.4)
Others/unknown 3 (2.5) 0 (0.0) 2 (1.7) 1 (0.8)
Current HAART regimen 11.309 .011
Double‐NRTIs + NNRTIs 103 (85.1) 9 (7.4) 16 (13.2) 78 (64.5)
Double‐NRTIs + PIs 14 (11.6) 2 (1.7) 2 (1.7) 10 (8.3)
Others/unknown 4 (3.3) 2 (1.7) 2 (1.7) 0 (0.0)
Note: The statistically significant are presented with italic bold.
Abbreviations: HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IDU, intravenous drug use; MCT, mother‐to‐child
transmission; NRTIs, nucleoside reverse‐transcriptase inhibitors; NNRTIs, nonnucleoside reverse‐transcriptase inhibitors; PIs, protease inhibitors.
aOthers/unknown include divorced, widowed, and others/unknown.
REN ET AL. | 5
The prevalence of HHVs was higher in the peripheral blood of
HIV‐positive individuals than in that of the control group. This finding
is in accordance with those of other studies, likely because of the
high sensitivity of our PCR assay.21 The eight HHVs except VZV were
more prevalent in HIV‐positive patients than in the control group.
Low EBV infection rates were observed both in the general
population and patients with HIV, may due to too small amount of
serum for extracting nucleic acid. HCMV and VZV were not detected
in the control group. The factors consistently and independently
associated with HHV infections were male sex, older age, being
married, high HIV viral load, mother‐to‐child transmission of HIV, and
current use of HAART regimen using PIs instead of NNRTIs.22 The
relationship between different HHV infections and immune status,
WHO HIV clinical stage, and HIV infection duration were not shown
in multivariate analysis, in spite of CD4 counts that were significantly
associated with the detection of EBV and HHV‐7 in univariate
analysis. However, older age was shown to have an important role
in the spread of multiple HHV infections in HIV‐positive patients
after adjusting for potential confounding factors.
The majority of the HIV‐seropositive groups (72.7%) were
positive with at least two detectable HHVs in peripheral blood
samples, compared with controls. The higher prevalence in the
HIV‐positive group may reflect an altered health status or
differences in the HHV seropositivity between groups. Risk factors
for VZV and HCMV were not readily evident due to the small
number of participants in this study. The prevalence of HSV‐1,
HHV‐6, and HHV‐8 infection was higher with increase in age.
Moreover, male sex and being married were strongly associated
with HSV‐1 infection. These phenomena were probably due to the
younger average age at marriage, lower socioeconomic status,
crowded living conditions, poor hygiene,23 and high levels of
concomitant HIV infection in male partners, which may enhance
HHVs infectivity of those partners.24 Plasma HIV viral load, CD4
count, and HAART therapy influenced each case of herpesvirus
infection in different ways.5,25 No significant correlations were
observed between the rate of HHV shedding and CD4 cell count or
plasma HIV‐1 RNA level among the HAART‐treated patients of
previous studies26,27 and our study.
The consequences of universal access to HAART include a
reduction in the number of deaths by AIDS and a reduction of the
incidence of opportunistic diseases.28 However, in this study, HHV
incidence appeared to persist at a higher frequency. Regarding the
impact of current HAART regimens for HHV infections, we can
conclude that patients treated with PIs instead of NNRTIs were at the
highest risk of HHV‐6 infection. As a second‐line treatment, PIs
instead of NNRTIs have been included in the HAART regimen for
patients with side effects or drug resistance.29 These findings suggest
that no single type of therapy is likely to reduce reactivation rates
among all classes of herpesviruses.25 Long‐term follow‐up studies are
needed to further confirm the influence on HHV infections by
different drugs. An important limitation of this study is that all
subjects lack follow‐up serostatus. In the future, longitudinal studies
should be performed involving HIV‐positive patients, before and after
initiating HAART with sufficient follow‐up and deaths for analysis, to
achieve a better understanding of the immune status and disease
progression. That might be important for predicting opportunistic
infections caused by these viruses. The correlation between the
infection rates of eight HHVs genotype and the genotypes of HIV
unique epidemic strains in Zhongtong was not clarified.
In conclusion, our study suggests that the frequency of the eight
HHVs and occurrence of more than two different HHVs in HIV‐
positive peripheral blood with HAART are significantly higher
compared with healthy controls when measured in a randomized
controlled design. The observations reported herein suggest that
the presence of HHVs in peripheral blood is a frequent event in
HIV‐infected individuals and increases the risk of multiple infections
in these patients, even in the presence of HAART therapy. These data
have confirmed that older age, being married, higher HIV‐1 plasma
viral load, and use of antiviral medicine PIs were correlated
independently with increased frequency of HHVs, but CD4 count,
WHO HIV clinical stage, and HIV infection duration were not
associated with HHVs. Our findings indicate that suppressing HHV
recurrences as a cotherapy to HAART had a clinically significant
effect on prolonging survival in some cohorts of HIV‐infected
patients and may be an effective intervention in reducing HIV
spread in China. Strategies to control HHVs deserve urgent attention
and should become part of the HIV‐1 prevention and care package.
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